Mr. Alan G. Goodman serves as the Chief Executive Officer and Chief Financial Officer at Avlar BioVentures Ltd. Mr. Goodman has over 20 years experience in the biotechnology and healthcare industries. Over the last 25 years, he co-founded many biotechnology and healthcare companies including Agricultural Genetics Company, Medeva PLC, Chiroscience. Group PLC, Acambis Plc, CeNeS Pharmaceuticals plc, Oxford BioMedica PLC, Core Group PLC and Amura Limited. He served as Finance Director at Avlar BioVentures Ltd. He served as Chief Executive Officer of Acambis Plc.. He worked at UCB Pharma Limited, Chiroscience Group plc (United Kingdom) and MicroBio Group Ltd. (The). He joined Medeva in 1989 to create a new independent pharmaceutical group by acquisition.. Mr. Goodman has been a Member of Supervisory Board at Paion AG since 31 July, 2008. He served as the Chairman of Takeda Cambridge Ltd (a/k/a Paradigm Therapeutics Limited); CeNeS Pharmaceuticals PLC; Alizyme Plc since July 2009 and CeNeS Pharmaceuticals plc. He served as the Non-Executive Chairman of Oxford BioMedica PLC. He serves as a Non-Executive Director of Amura Ltd. (a/k/a Amura Holdings Limited), Sterix Limited and Aclar Limited. He served as a Non-Executive Director of Incenta Ltd, De Novo Pharmaceuticals, Ltd., Amedis Pharmaceuticals Limited. He served as Director of Alizyme Plc since April 23, 2009.. He served as a Board Member of Regenerative Medicine Assets Limited (a/ka Intercytex Limited) until July 21, 2005. He served as a Non-Executive Director of Aitua Limited.. Mr. Goodman is C.M.A.
